Lupin获欧盟委员会批准其生物类似药雷珠单抗

LootboxPhobia · 2026-02-23T11:25:56+00:00

Lupin announced on Monday that it has received approval from the European Commission for its biosimilar drug, Rituximab, allowing it to be sold in the European Union. The move aims to provide patients with alternative treatment options and expand Lupin's product portfolio in the European market.

LootboxPhobia

2026-02-23 11:25:56

Abstract generation in progress

Investing.com – Lupin announced on Monday that the pharmaceutical company has received approval from the European Commission for its biosimilar drug, Ranibizumab.

This approval allows Lupin to sell a biosimilar version of Ranibizumab in EU member states. Ranibizumab is used to treat various eye conditions, including age-related macular degeneration and diabetic retinopathy.

The European Commission’s decision was made after an assessment process evaluating the biosimilar’s similarity to the reference product in terms of quality, safety, and efficacy.

Lupin’s biosimilar Ranibizumab will provide an alternative treatment option for patients in Europe who need this medication. This approval marks an expansion of Lupin’s biosimilar product portfolio in the European market.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.